Betamethasone phonophoresis to help repigment vitiligo patches
Effect of Betamethasone Phonophoresis in Treatment of Vitiligo
This trial will try using betamethasone delivered with therapeutic ultrasound (phonophoresis) to help people with vitiligo regain skin pigment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 25 Years to 40 Years |
| Sex | All |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT07267273 on ClinicalTrials.gov |
What this trial studies
This interventional study applies a mid-potency topical corticosteroid (betamethasone) using therapeutic ultrasound (phonophoresis) to enhance skin penetration at sites of vitiligo. Eligible patients will attend treatment sessions at Cairo University Hospital and be followed over time with clinical exams and standardized photographs to document repigmentation and side effects. The study will monitor for local and systemic steroid adverse events and exclude patients with pregnancy, active infections, systemic immunosuppression, or current phototherapy. Treatment response will be measured as change in pigmentation of enrolled lesions compared with baseline.
Who should consider this trial
Good fit: Ideal candidates are medically and psychologically stable adults with vitiligo who can consent, have no contraindication to therapeutic ultrasound, and are not on systemic immunosuppressants or phototherapy.
Not a fit: Patients who are pregnant or lactating, immunosuppressed, have active skin infections, are receiving systemic immunosuppressants or phototherapy, or have unstable/progressive disease are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, this approach could improve repigmentation of vitiligo patches by increasing local steroid delivery while minimizing systemic exposure.
How similar studies have performed: Phonophoresis has been used to boost topical drug delivery in other conditions, but its specific benefit for vitiligo is novel with limited prior data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female patients diagnosed with vitiligo. * Medically and psychologically stable patients. * Good cognitive abilities to understand the requirements of the study. * All patients enrolled to the study will have their informed consent. * they had no contraindications to the use of therapeutic ultrasound Exclusion Criteria: * Pregnancy or lactation. * Immunosuppression. * Alcohol abuse. * History of spontaneous re-pigmentation of lesions. * Presence of skin characteristics that may interfere with study assessment. * Active bacterial/viral infection. * Patients on other immune suppressants and phototherapy * Patients currently participating in any other clinical study * Uncooperative patients.
Where this trial is running
Cairo
- Cairo University Hospital — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Ola Sabry Abd-Elmaksoud Tarabya, MSc
- Email: Olasabry17@yahoo.com
- Phone: +201024035447
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.